Skip to main content
. 2017 Oct 4;7(6):1013–1020. doi: 10.3892/mco.2017.1442

Table II.

Therapeutic effects in all patients (n=64).

Therapeutic effect Sorafenib (n=20) NFP (n=44)
CR 0 (0) 10 (23)
PR 2 (10) 21 (48)
SD 8 (40) 8 (18)
PD 10 (50) 5 (11)

NFP, new 5-fluorouracil and cisplatin therapy; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease Results are presented as n (%).